Centers for Medicare & Medicaid Services (CMS) recently released its List of Measures under Consideration.
One of the measures under consideration is MUC17-210 which measures “Hospital Harm Performance Measure: Opioid Related Adverse Respiratory Events”:
“This measure will assess opioid related adverse respiratory events (ORARE) in the hospital setting. The goal for this measure is to assess the rate at which naloxone is given for opioid related adverse respiratory events that occur in the hospital setting, using a valid method that reliably allows comparison across hospitals.”
Continue reading “CMS Proposes Measuring Opioid Related Adverse Respiratory Events”
To reverse the effects of opioid-induced respiratory depression, the FDA recommends the use of naloxone:
When someone overdoses on an opioid, it can be difficult to awaken the person, and breathing may become shallow or stop – leading to death if there is no medical intervention. If naloxone is administered quickly, it can counter the overdose effects, usually within two minutes.
However, there are three must knows before using naloxone to reverse the effects of opioid-induced respiratory depression. Continue reading “Three Must Knows Before Using Naloxone to Reverse the Effects of Opioid-Induced Respiratory Depression”